Harrison Kim1, John V Thomas2, Jeffrey W Nix3, Jennifer B Gordetsky4, Yufeng Li5, Soroush Rais-Bahrami6. 1. Department of Radiology, University of Alabama at Birmingham, G082C5 Volker Hall, 1670 University Blvd., Birmingham, AL 35294-0019; O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL. Electronic address: hyunkikim@uabmc.edu. 2. Department of Radiology, University of Alabama at Birmingham, G082C5 Volker Hall, 1670 University Blvd., Birmingham, AL 35294-0019. 3. Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama; O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL. 4. Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama. 5. Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. 6. Department of Radiology, University of Alabama at Birmingham, G082C5 Volker Hall, 1670 University Blvd., Birmingham, AL 35294-0019; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama; O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL.
Abstract
RATIONALE AND OBJECTIVES: The study goal was to test whether the improved accuracy in quantitative dynamic contrast-enhanced magnetic resonance imaging measurement using a point-of-care portable perfusion phantom (P4) leads to better stratification of prostate cancer grade. MATERIALS AND METHODS: A prospective clinical study was conducted recruiting 44 patients scheduled for multi-parameter MRI prostate exams. All participants were imaged with the P4 placed under their pelvic regions. Tissue sampling was carried out for 25 patients at 22 ± 18 (mean ± SD) days after multi-parameter MRI. On histologic examination, a total of 31 lesions were confirmed as prostate cancer. Tumors were classified into low grade (n = 14), intermediate grade (n = 10), and high grade (n = 7). Tumor perfusion was assessed by volume transfer constant, Ktrans, before and after P4-based error correction, and the Ktrans of low, intermediate and high-grade tumors were statistically compared. RESULTS: After P4-based error correction, the Ktrans of low, intermediate, and high-grade tumors were 0.109 ± 0.026 min-1 (95% CI: 0.0094 to 0.124 min-1), 0.163 ± 0.049 min-1 (95% CI: 0.129 to 0.198 min-1) and 0.356 ± 0.156 min-1 (95% CI: 0.215 to 0.495 min-1), respectively, with statistically significant difference among the groups (low vs intermediate: p = 0.002; intermediate vs high: p = 0.002; low vs high: p < 0.001). The sensitivity and specificity of Ktrans value, 0.14 min-1, to detect the clinically significant prostate cancer were 88% and 93%, respectively, after P4 based error correction, but those before error correction were 88% and 86%, respectively. CONCLUSION: The P4 allows to reduce errors in quantitative dynamic contrast-enhanced magnetic resonance imaging measurement, enhancing accuracy in stratification of prostate cancer grade.
RATIONALE AND OBJECTIVES: The study goal was to test whether the improved accuracy in quantitative dynamic contrast-enhanced magnetic resonance imaging measurement using a point-of-care portable perfusion phantom (P4) leads to better stratification of prostate cancer grade. MATERIALS AND METHODS: A prospective clinical study was conducted recruiting 44 patients scheduled for multi-parameter MRI prostate exams. All participants were imaged with the P4 placed under their pelvic regions. Tissue sampling was carried out for 25 patients at 22 ± 18 (mean ± SD) days after multi-parameter MRI. On histologic examination, a total of 31 lesions were confirmed as prostate cancer. Tumors were classified into low grade (n = 14), intermediate grade (n = 10), and high grade (n = 7). Tumor perfusion was assessed by volume transfer constant, Ktrans, before and after P4-based error correction, and the Ktrans of low, intermediate and high-grade tumors were statistically compared. RESULTS: After P4-based error correction, the Ktrans of low, intermediate, and high-grade tumors were 0.109 ± 0.026 min-1 (95% CI: 0.0094 to 0.124 min-1), 0.163 ± 0.049 min-1 (95% CI: 0.129 to 0.198 min-1) and 0.356 ± 0.156 min-1 (95% CI: 0.215 to 0.495 min-1), respectively, with statistically significant difference among the groups (low vs intermediate: p = 0.002; intermediate vs high: p = 0.002; low vs high: p < 0.001). The sensitivity and specificity of Ktrans value, 0.14 min-1, to detect the clinically significant prostate cancer were 88% and 93%, respectively, after P4 based error correction, but those before error correction were 88% and 86%, respectively. CONCLUSION: The P4 allows to reduce errors in quantitative dynamic contrast-enhanced magnetic resonance imaging measurement, enhancing accuracy in stratification of prostate cancer grade.
Authors: Roberto Alonzi; Anwar R Padhani; N Jane Taylor; David J Collins; James A D'Arcy; J James Stirling; Michele I Saunders; Peter J Hoskin Journal: Int J Radiat Oncol Biol Phys Date: 2010-07-12 Impact factor: 7.038
Authors: Hersh Chandarana; Li Feng; Tobias K Block; Andrew B Rosenkrantz; Ruth P Lim; James S Babb; Daniel K Sodickson; Ricardo Otazo Journal: Invest Radiol Date: 2013-01 Impact factor: 6.016
Authors: Baris Turkbey; Andrew B Rosenkrantz; Masoom A Haider; Anwar R Padhani; Geert Villeirs; Katarzyna J Macura; Clare M Tempany; Peter L Choyke; Francois Cornud; Daniel J Margolis; Harriet C Thoeny; Sadhna Verma; Jelle Barentsz; Jeffrey C Weinreb Journal: Eur Urol Date: 2019-03-18 Impact factor: 20.096
Authors: Harrison Kim; Desiree E Morgan; Patrick Schexnailder; Rudolph M Navari; Grant R Williams; J Bart Rose; Yufeng Li; Ravikumar Paluri Journal: Invest Radiol Date: 2019-01 Impact factor: 6.016
Authors: Martin D Holland; Andres Morales; Sean Simmons; Brandon Smith; Samuel R Misko; Xiaoyu Jiang; David A Hormuth; Chase Christenson; Roy P Koomullil; Desiree E Morgan; Yufeng Li; Junzhong Xu; Thomas E Yankeelov; Harrison Kim Journal: Med Phys Date: 2021-12-10 Impact factor: 4.506